Evidence map›Paper›PMID 28220020›Full record

Trial reportThe oncologist2017

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Linda T Vahdat, Rachel Layman, Denise A Yardley, William Gradishar, Mohamad A Salkeni, Anil Joy, Agustin A Garcia, Patrick Ward, James Khatcheressian, Joseph Sparano and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 2 countries.

Linda T VahdatWeill Cornell Breast Center, Weill Cornell Medicine, New York, New York, USA ltv2001@med.cornell.edu.
Rachel LaymanOhio State University, Columbus, Ohio, USA.
Denise A YardleyTennessee Oncology, Nashville, Tennessee, USA.
William GradisharNorthwestern University Feinburg School of Medicine, Chicago, Illinois, USA.
Mohamad A SalkeniMary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, West Virginia, USA.
Anil JoyUniversity of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada.
Agustin A GarciaNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
Patrick WardOncology Hematology Care Incorporated, Cincinnati, Ohio, USA.
James KhatcheressianVirginia Cancer Institute, Richmond, Virginia, USA.
Joseph SparanoWeiler Division, Montefiore Medical Center, Bronx, New York, USA.
Gladys RodriguezSouth Texas Oncology and Hematology, San Antonio, Texas, USA.
Shande TangEli Lilly and Company, Indianapolis, Indiana, USA.
Ling GaoEli Lilly and Company, Indianapolis, Indiana, USA.
Rita P DalalEli Lilly and Company, Indianapolis, Indiana, USA.
John KauhEli Lilly and Company, Indianapolis, Indiana, USA.
Kathy MillerMelvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana, USA.
Eli Lilly (United States) · USIndiana University Health · USMontefiore Medical Center · USNorthwestern University · USOncology Hematology Care · USTennessee Oncology · USTexas Oncology · USThe Ohio State University · USUniversity of Alberta · CAUniversity of Southern California · USVirginia Cancer Institute · USWeill Cornell Medicine · USWest Virginia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIcrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2), respectively. This open-label, randomized phase II study evaluated their efficacy and safety in combination with capecitabine (CAP) in patients with previously treated unresectable, locally advanced or metastatic breast cancer.

methodsPatients were randomly assigned (1:1:1) to receive CAP (1,000 mg/m

resultsOf 153 patients randomized, 150 received treatment. Median PFS (95% confidence interval) was 22.1 (12.1-36.1) weeks on RAM + CAP, 7.3 (6.3-13.0) weeks on ICR + CAP, and 19.0 (12.1-24.3) weeks on CAP (hazard ratios [HRs]: 0.691,

conclusionCombining RAM or ICR with CAP did not improve PFS in the targeted study population.

Indexed as

AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineDisease-Free SurvivalDrug-Related Side Effects and Adverse ReactionsDrug Resistance, NeoplasmFemaleHumansMiddle AgedNeovascularization, PathologicRamucirumabVascular Endothelial Growth Factor AAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCapecitabineIcrucumabRamucirumabVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Breast cancerCapecitabineDrug resistanceMetastasisMonoclonal antibodies

Identifiers

PMID28220020
PMCPMC5344637
OpenAlexW2591046956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.